9 hasil untuk "Brian Higgins"
Menampilkan 1–9 · 0,29 detik · RSS
-
Artikel Jurnal
Supporting Early and Ongoing University Student Experiences Through ‘Academic Skills Adviser’ Services
Academic support for first year students is critical for improving engagement, retention and completion rates at one of Australia’s smallest but fastest-growing universities. A model of Academic Skills Adviser (ASA) support developed over recent years at the University of the Sunshine Coast (USC)…
-
Artikel Jurnal Teks lengkap
BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.
Cross-feedback activation of MAPK and AKT pathways is implicated as a resistance mechanism for cancer therapeutic agents targeting either RAF/MEK or PI3K/AKT/mTOR. It is thus important to have a better understanding of the molecular resistance mechanisms to improve patient survival benefit from…
Juga tersedia di: PLOS
-
Artikel Jurnal
Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease
Abstract Whilst it is recognised that targeting self-renewal is an effective way to functionally impair the quiescent leukaemic stem cells (LSC) that persist as residual disease in chronic myeloid leukaemia (CML), developing therapeutic strategies to achieve this have proved challenging. We…
-
Artikel Jurnal
MDM2 Antagonists Counteract Drug-Induced DNA Damage
Antagonists of MDM2-p53 interaction are emerging anti-cancer drugs utilized in clinical trials for malignancies that rarely mutate p53, including melanoma. We discovered that MDM2-p53 antagonists protect DNA from drug-induced damage in melanoma cells and patient-derived xenografts. Among the tested…
-
Artikel Jurnal
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial
Pentraxin 2 (PTX-2; serum amyloid P component), a circulating endogenous regulator of the inflammatory response to tissue injury and fibrosis, is reduced in patients with myelofibrosis (MF). Zinpentraxin alfa (RO7490677, PRM-151) is a recombinant form of PTX-2 that has shown preclinical…
-
Artikel Jurnal
BRD4-mediated repression of p53 is a target for combination therapy in AML
MDM2 and BET inhibitors have shown efficacy in AML treatment. Here, the authors show that the two compounds can synergize through both p53 protein stabilization and inhibition of BRD4-mediated repression of p53 target genes.